Besides, we have also found that antitumor necrosis factor-α (anti-TNF-α) agents may improve insulin resistance in patients with moderate-to-severe psoriasis [8], although no significant changes in serum leptin or resistin concentrations after 6 months of adalimumab therapy were found [6]. The gene discussed is LEP; the disease is Insulin resistance.